177 related articles for article (PubMed ID: 33600264)
1. Long non-coding RNA MEG3 as a candidate prognostic factor for induction therapy response and survival profile in childhood acute lymphoblastic leukemia patients.
Gao W
Scand J Clin Lab Invest; 2021 May; 81(3):194-200. PubMed ID: 33600264
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of long non coding maternally expressed gene 3 in pediatric acute myeloid leukemia.
Xue H; Gao H; Xia H; Li S; Li N; Duan Y; Ren Y; Zhang H; Liu J; Gao W
Medicine (Baltimore); 2021 Sep; 100(35):e26959. PubMed ID: 34477125
[TBL] [Abstract][Full Text] [Related]
3. IncRNA MVIH correlates with disease features, predicts treatment response and survival in pediatric acute myeloid leukemia.
Xue H; Gao H; Xia H; Li S; Li N; Gao C; Duan Y; Ren Y; Zhang H; Liu J; Gao W
J Clin Lab Anal; 2021 Apr; 35(4):e23739. PubMed ID: 33704838
[TBL] [Abstract][Full Text] [Related]
4. Lnc-MEG3 acts as a potential biomarker for predicting increased disease risk, systemic inflammation, disease severity, and poor prognosis of sepsis via interacting with miR-21.
Na L; Ding H; Xing E; Gao J; Liu B; Wang H; Yu J; Yu C
J Clin Lab Anal; 2020 Apr; 34(4):e23123. PubMed ID: 31907972
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
6. The relationship of long non-coding RNA maternally expressed gene 3 with microRNA-21 and their correlation with acute ischemic stroke risk, disease severity and recurrence risk.
Liu C; Huang H; Li Y; Zhao H
Clin Neurol Neurosurg; 2021 Nov; 210():106940. PubMed ID: 34607195
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of miR-335-3p, targeted by NEAT1 and MALAT1 long non-coding RNAs, is associated with poor prognosis in childhood acute lymphoblastic leukemia.
Pouyanrad S; Rahgozar S; Ghodousi ES
Gene; 2019 Apr; 692():35-43. PubMed ID: 30639603
[TBL] [Abstract][Full Text] [Related]
8. Baseline lncRNA PCAT1 high expression and its longitude increment during induction therapy predict worse prognosis in multiple myeloma patients.
Zhao P; Zhao X
J Clin Lab Anal; 2021 Nov; 35(11):e23924. PubMed ID: 34564896
[TBL] [Abstract][Full Text] [Related]
9. Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients.
Xu J; Zhao L
J Pediatr Hematol Oncol; 2023 May; 45(4):189-194. PubMed ID: 35973104
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 Decrease During Induction Therapy Could Indicate Good Treatment Response, Favorable Risk Stratification, and Prolonged Survival in Pediatric Acute Lymphoblastic Leukemia.
Zhao Y; Li C; Cai C; Fu H; Zhao Z; Han J; Zhang F; Wang J
J Pediatr Hematol Oncol; 2023 Aug; 45(6):e739-e745. PubMed ID: 36897339
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of Relationship between Long Non-Coding RNA Small Nucleolar RNA Host Gene 1 and Acute Myeloid Leukemia Risk and Prognosis in Pediatric Patients].
Su W; Hong Y; Jiang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1127-1136. PubMed ID: 32798387
[TBL] [Abstract][Full Text] [Related]
12. Correlation analysis of long non-coding RNA TUG1 with disease risk, clinical characteristics, treatment response, and survival profiles of adult Ph
Zeng P; Chai Y; You C; Yue L; Wu C; Chen H; Li L; Li J; Liu H; Zhang Y; Cao T; Li Y; Hu W
J Clin Lab Anal; 2021 Aug; 35(8):e23583. PubMed ID: 34251066
[TBL] [Abstract][Full Text] [Related]
13. Retraction: The
Zeng P; Chai Y; You C; Yue L; Wu C; Chen H; Li L; Li J; Liu H; Zhang Y; Cao T; Li Y; Hu W
Turk J Haematol; 2022 Aug; 39(3):188-195. PubMed ID: 35657175
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA T-cell factor 7 in multiple myeloma: A potential biomarker for deteriorated clinical features and poor prognosis.
Zhang C; Chu M; Fan Y; Wu L; Li Z; Ma X; Zhuang W
J Clin Lab Anal; 2020 Sep; 34(9):e23400. PubMed ID: 32578294
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.
Stamati L; Avgeris M; Kosmidis H; Baka M; Anastasiou T; Piatopoulou D; Scorilas A; Gourgiotis D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2023-36. PubMed ID: 25982455
[TBL] [Abstract][Full Text] [Related]
16. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
17. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia.
Choi J; Hwang YK; Sung KW; Lee SH; Yoo KH; Jung HL; Koo HH; Kim HJ; Kang HJ; Shin HY; Ahn HS
Blood; 2007 Jan; 109(2):471-7. PubMed ID: 16990595
[TBL] [Abstract][Full Text] [Related]
18. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
19. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
20. Lnc-SOX6-1 upregulation correlates with poor risk stratification and worse treatment outcomes, and promotes cell proliferation while inhibits apoptosis in pediatric acute myeloid leukemia.
Guan X; Wen X; Xiao J; An X; Yu J; Guo Y
Int J Lab Hematol; 2019 Apr; 41(2):234-241. PubMed ID: 30624855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
